Literature DB >> 33973193

Therapeutic Development in COVID-19.

Chan Yang1, Yuan Huang1, Shuwen Liu2,3,4.   

Abstract

Since the outbreak of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2, the disease has spread rapidly worldwide and developed into a global pandemic, causing a significant impact on the global health system and economic development. Scientists have been racing to find effective drugs and vaccines for the treatment and prevention of COVID-19. However, due to the diversity of clinical manifestations caused by COVID-19, no standard antiviral regimen beyond supportive therapy has been established. Ongoing clinical trials are underway to evaluate the efficacy of drugs that primarily act on the viral replication cycle or enhanced immunity of patients. This chapter will summarize the currently used antiviral and adjuvant therapies in clinical practice and provide a theoretical basis for the future treatment of COVID-19.

Entities:  

Keywords:  Antiviral; COVID-19; Drugs; SARS-CoV-2; Therapy

Mesh:

Substances:

Year:  2021        PMID: 33973193     DOI: 10.1007/978-3-030-63761-3_25

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  53 in total

1.  Single-chain antibodies against a plant viral RNA-dependent RNA polymerase confer virus resistance.

Authors:  KaJohn Boonrod; Danuta Galetzka; Peter D Nagy; Udo Conrad; Gabi Krczal
Journal:  Nat Biotechnol       Date:  2004-06-13       Impact factor: 54.908

2.  Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions.

Authors:  Megan J Brooks; Elena I Burtseva; Philip J Ellery; Glenn A Marsh; Andrew M Lew; Anatoly N Slepushkin; Suzanne M Crowe; Gregory A Tannock
Journal:  J Med Virol       Date:  2011-10-25       Impact factor: 2.327

3.  Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.

Authors:  Kanchan Anand; John Ziebuhr; Parvesh Wadhwani; Jeroen R Mesters; Rolf Hilgenfeld
Journal:  Science       Date:  2003-05-13       Impact factor: 47.728

Review 4.  Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2018-07       Impact factor: 11.431

5.  Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity.

Authors:  Anna C C Aguiar; Erika Murce; Wilian A Cortopassi; Andre S Pimentel; Maria M F S Almeida; Daniele C S Barros; Jéssica S Guedes; Mario R Meneghetti; Antoniana U Krettli
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-10-13       Impact factor: 4.077

6.  Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.

Authors:  Ariane J Brown; John J Won; Rachel L Graham; Kenneth H Dinnon; Amy C Sims; Joy Y Feng; Tomas Cihlar; Mark R Denison; Ralph S Baric; Timothy P Sheahan
Journal:  Antiviral Res       Date:  2019-06-21       Impact factor: 5.970

7.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.

Authors:  Emmie de Wit; Friederike Feldmann; Jacqueline Cronin; Robert Jordan; Atsushi Okumura; Tina Thomas; Dana Scott; Tomas Cihlar; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-13       Impact factor: 11.205

8.  Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.

Authors:  Xiangyu Chen; Ren Li; Zhiwei Pan; Chunfang Qian; Yang Yang; Renrong You; Jing Zhao; Pinghuang Liu; Leiqiong Gao; Zhirong Li; Qizhao Huang; Lifan Xu; Jianfang Tang; Qin Tian; Wei Yao; Li Hu; Xiaofeng Yan; Xinyuan Zhou; Yuzhang Wu; Kai Deng; Zheng Zhang; Zhaohui Qian; Yaokai Chen; Lilin Ye
Journal:  Cell Mol Immunol       Date:  2020-04-20       Impact factor: 11.530

9.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

10.  Convalescent plasma as a potential therapy for COVID-19.

Authors:  Long Chen; Jing Xiong; Lei Bao; Yuan Shi
Journal:  Lancet Infect Dis       Date:  2020-02-27       Impact factor: 25.071

View more
  1 in total

Review 1.  How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?

Authors:  Nabil G Seidah; Antonella Pasquato; Ursula Andréo
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.